Friday, 16 October 2026European Markets

FLOW TRADERS And ROTHSCHILD & CO Have A High Dividend Yield And Return On Equity In The Capital Markets Industry.

Loading stream...

(vianews) - flow traders (flow.as) is among this list of stock assets with the highest dividend rate and return on equity on the capital markets industry.

financial asset price forward dividend yield return on equity
flow traders (flow.as) €26.48 7.07% 22.76%
rothschild & co (roth.pa) €46.65 3% 21.08%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. flow traders (flow.as)

7.07% forward dividend yield and 22.76% return on equity

flow traders ltd. operates as a financial technology-enabled multi-asset class liquidity provider in europe, the americas, and asia. the company provides liquidity that allows investors to continue to buy or sell exchange traded products or other financial instruments. it offers liquidity through on screen, which is conducted on stock exchanges; and off exchange through request for quote platforms. the company was founded in 2004 and is headquartered in amsterdam, the netherlands.

earnings per share

as for profitability, flow traders has a trailing twelve months eps of €5.58.

pe ratio

flow traders has a trailing twelve months price to earnings ratio of 4.74. meaning, the purchaser of the share is investing €4.74 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.76%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, flow traders's stock is considered to be oversold (<=20).

dividend yield

according to morningstar, inc., the next dividend payment is on apr 28, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 7.07%.

more news about flow traders.

2. rothschild & co (roth.pa)

3% forward dividend yield and 21.08% return on equity

rothschild & co sca provides global advisory, wealth and asset management, and merchant banking services in france, the united kingdom, the channel islands, the americas, rest of europe, switzerland, australia, asia, and internationally. the company offers merger and acquisition, strategic advisory; debt advisory and restructuring; and equity advisory services, which include ecm advisory, private capital, and investor advisory and marketing services. it also provides wealth management services to successful families, individuals, foundations and charities; and asset management services, such as bespoke investment management and advisory services to institutional clients, financial intermediaries, and third-party distributors. in addition, the company offers merchant banking services, including corporate private equity, multi strategies, direct lending, and credit management. rothschild & co sca was founded in 1838 and is headquartered in paris, france.

earnings per share

as for profitability, rothschild & co has a trailing twelve months eps of €2.19.

pe ratio

rothschild & co has a trailing twelve months price to earnings ratio of 21.3. meaning, the purchaser of the share is investing €21.3 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.08%.

volume

today's last reported volume for rothschild & co is 10655 which is 77.46% below its average volume of 47291.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 29, 2023, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 3%.

more news about rothschild & co.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com